Trial Profile

A Phase 1, dose escalation clinical trial will evaluate the safety and tolerability, as well as key biologic endpoints of CYTO-102 as a monotherapy or in combination with atezolizumab in patients with relapsed/refractory non-small cell lung cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Nov 2022 According to CytoImmune Therapeutics media release, initial clinical data from this trial is expected in 2023
28 Jul 2022 According to CytoImmune Therapeutics media release, this study is initiated in partnership with City of Hope
28 Jul 2022 Status changed from planning to recruiting, according to CytoImmune Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com